Atezolizumab
Atezolizumab is an anti-PD-L1 monoclonal antibody immunotherapy drug used to treat various cancers including bladder (urothelial carcinoma), lung (NSCLC), breast (TNBC), and melanoma. It works by blocking the PD-L1 protein on tumor cells, which allows the immune system to recognize and attack cancer cells more effectively.
Atezolizumab is an immunotherapy drug that blocks PD-L1 to help the immune system fight certain cancers.
Key facts at a glance
- ATC
- L01FF05
- RxNorm
- 1792776
- Generic
- Atezolizumab
- Class
- atc-l01
- Brands
- Tecentriq, Tecentriq Hybreza
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- injection
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 1200mg every 3 weeks
- Maximum
- consult physician
- Frequency
- every 3 weeks
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- Not established for pediatric use
- Maximum
- consult physician
- Frequency
- N/A
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 1200mg every 3 weeks
- Maximum
- consult physician
- Frequency
- every 3 weeks
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
8 groupspregnancy
first trimesteravoid if possible
avoid use during pregnancy unless benefits outweigh risks to the fetus
regular fetal monitoring and ultrasound assessments
Use of this medication in this population requires careful consideration of risks and benefits.
pregnancy
second third trimesteravoid if possible
discontinue therapy if pregnancy occurs; consider risks versus benefits
Use of this medication in this population requires careful consideration of risks and benefits.
lactation
breastfeedingnot recommended
discontinue breastfeeding during treatment and for at least 5 months after last dose
no specific monitoring required
geriatric
elderly 65 and olderno specific adjustment
use with caution; no dose adjustment required but monitor for adverse effects
regular assessment of organ function and immune-related adverse events
Use with caution and monitor for adverse effects.
pediatric_age
children under 18not established
safety and efficacy not established in pediatric patients; use only in clinical trials
monitor growth and development if treatment necessary
renal_impairment
mild moderate severeno adjustment needed
no dose adjustment required for mild, moderate, or severe renal impairment
routine monitoring of renal function
hepatic_impairment
mildno adjustment needed
no dose adjustment required for mild hepatic impairment
routine liver function monitoring
hepatic_impairment
moderate severeuse with caution
use with caution; limited data in moderate to severe hepatic impairment; consider risks versus benefits
close monitoring of liver function tests
Use with caution and monitor for adverse effects.
Statistics and clinical data
FDA approval year
Initial FDA approval date for Atezolizumab (Tecentriq)
Drug class
Atezolizumab is a programmed death-ligand 1 (PD-L1) blocking antibody
Approved indications
Major approved therapeutic indications for Atezolizumab
Route of administration
Method of drug administration
Atezolizumab is FDA-approved for the treatment of urothelial carcinoma (bladder cancer), non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), small cell lung cancer (SCLC), and melanoma. It may be used alone or in combination with other cancer treatments depending on the specific cancer type and stage.
Atezolizumab is a monoclonal antibody that binds to PD-L1 protein, which may be expressed on tumor cells and tumor-infiltrating immune cells. By blocking PD-L1 from binding to PD-1 and B7.1 receptors on T cells and antigen-presenting cells, it removes the brake on the immune system, allowing T cells to recognize and destroy cancer cells.
Atezolizumab is administered by intravenous infusion. Common side effects include fatigue, decreased appetite, nausea, and immune-related adverse events. Patients should be monitored for immune-mediated reactions affecting the lungs, liver, colon, and endocrine glands. Treatment should be supervised by oncologists experienced in immunotherapy.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy